Veru VERU 深 沪
等待开盘 07-31 09:30:00 美东时间
0.4934
+0.002
+0.35%
华盛通- 最 高0.5181
- 今 开0.50
- 成交量 80.74万股
- 最 低 0.493
- 昨 收 0.4917
- 总市值 7252.98万
- 52周最高 1.42
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 0.45
- 委 比 0.00%
- 总股本 1.47亿
- 历史最高 24.57
- 量 比 0.50
- 振 幅 5.10%
- 历史最低 0.36
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Synergy CHC secures retail deals with McKesson Canada and others
Synergy CHC (NASDAQ:SNYR) announced on Monday a new wave of retail and distribution wins across its FOCUSfactor supplement and functional beverage lines. London Drugs, one of Canada’s most trusted ph...
07-14 21:22
阿尔茨海默病被发现百年，药物研发为何成制药企业“坟场”？
来源：反做空一线 文/山有信 “价格已经翻倍了！”“什么时候才能正常买到甘露特钠？我爸要断药了。”近日，在国内某社交媒体平台上，不少阿尔兹海默病（以...
07-01 23:55
PLBY Group completes corporate name change to Playboy
Playboy (NASDAQ:PLBY) has announced that it has legally completed its corporate name change from PLBY Group to Playboy. The new corporate name aligns the Co.’s flagship Playboy brand with its corporat...
06-25 20:42
Veru Reports Topline Efficacy And Safety Results From Maintenance Extension Portion Of Phase 2b QUALITY Study, Demonstrating that In 12 Weeks After Stopping Semaglutide, Placebo Monotherapy Group Regained 43% Of Body Weight While Enobosarm Monotherapy Reduced Weight Regain By 46%
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average,
06-24 20:33
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
Veru公司的Phase 2b QUALITY研究显示，使用enobosarm 3mg在停止semaglutide后显著减少了46%的体重回升，并完全阻止脂肪恢复。与安慰剂相比，enobosarm组脂肪损失增加93%，且完全保留肌肉质量。该药物在12周的维持期内展现出良好的安全性，无明显胃肠道副作用。基于研究结果，Veru计划推进3mg剂量的enobosarm进入Phase 3临床试验，并已安排与FDA讨论后续研究计划。
06-24 12:30
减肥不掉肌肉！礼来新药联用Wegovy取得惊喜试验结果
①礼来公司在ADA大会上公布，其实验性药物与诺和诺德的减肥针Wegovy联合使用，能帮助患者在减重同时维持肌肉量； ②数据显示，联合使用48周后，患者体重平均减少22.1%，其中92.8%来自脂肪，而仅使用Wegovy的患者体重减少15.7%，脂肪减少比例有所下降。
06-24 03:38
Veru to Participate in the Virtual BTIG Obesity Health Forum
Veru Inc., a late-stage biopharmaceutical company, announced its participation in the virtual BTIG Obesity Health Forum on June 18, 2025. The company focuses on developing innovative medicines for cardiometabolic and inflammatory diseases, with two key drug candidates: enobosarm, a next-generation selective androgen receptor modulator (SARM) for enhanced fat loss in obesity treatment, and sabizabulin, a microtubule disruptor targeting inflammatio...
06-11 12:30
GrowGeneration announces distribution agreement across EU
GrowGeneration (NASDAQ:GRWG) on Tuesday said it has entered into a distribution agreement with V1 Solutions, a Macedonia-based company that will act as GrowGen’s sales and marketing partner for its pr...
06-10 20:06
GrowGeneration acquires Viagrow, expands into home gardening market
GrowGeneration (NASDAQ:GRWG) on Monday announced its acquisition of Viagrow, a domestic supplier of gardening and hydroponic equipment, in a move that expands the company’s presence in the home garden...
06-09 20:24
Cibus announces pricing of $27.5M public offering
Cibus (NASDAQ:CBUS) on Thursday announced the pricing of its public offering of 15.71M shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strate...
06-05 21:47
